Comprehensive molecular characterization of gastric adenocarcinoma
Open accessThe DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Abstract
Gastric cancer is a leading cause of cancer deaths, but analysis of its molecular and clinical characteristics has been complicated by histological and aetiological heterogeneity. Here we describe a comprehensive molecular evaluation of 295 primary gastric adenocarcinomas as part of The Cancer Genome Atlas (TCGA) project. We propose a molecular classification dividing gastric cancer into four subtypes: tumours positive for Epstein–Barr virus, which display recurrent PIK3CA mutations, extreme DNA hypermethylation, and amplification of JAK2, CD274 (also known as PD-L1) and PDCD1LG2 (also known as PD-L2); microsatellite unstable tumours, which show elevated mutation rates, including mutations of genes encoding targetable oncogenic signalling proteins; genomically stable tumours, which are enriched for the diffuse histological variant and mutations of RHOA or fusions involving RHO-family GTPase-activating proteins; and tumours with chromosomal instability, which show marked aneuploidy and focal amplification of receptor tyrosine kinases. Identification of these subtypes provides a roadmap for patient stratification and trials of targeted therapies. The Cancer Genome Atlas reports on molecular evaluation of 295 primary gastric adenocarcinomas and proposes a new classification of gastric cancers into 4 subtypes, which should help with clinical assessment and trials of targeted therapies. This contribution from The Cancer Genome Atlas (TCGA) project describes the molecular evaluation of 295 primary gastric adenocarcinomas. Based on the results, the authors propose a novel classification separating gastric cancers into four subtypes according to: Epstein–Barr virus positive status, microsatellite instability, chromosomal instability or genomic stability. Given the histologic and etiologic heterogeneity of gastric cancer identification of these subtypes, using a schema that can readily be applied to patient samples should help with patient stratification and trials of targeted therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Many of the miRNAs were also reported by a recent systems biology paper from TCGA in 2014 [34].”
From Bioinformatic Interrogation of 5p-arm and 3p-arm Specific miRNA Expression Using TCGA Datasets (2015) · cites this paper as [34]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The fusion of this evidence has prompted TCGA and the Asian Cancer Research Group (ACRG) to propose several molecular classifications [77,78].”
From Bioinformatics Analysis and Validation of Potential Markers Associated with Prediction and Prognosis of Gastric Cancer (2024) · cites this paper as [77]
The cited source says what the claim attributes to it.
In the citing paper
“The TP53/APC double knockout (DKO) organoid line was established in our previous studies by sequentially disrupting TP53 and APC37, two common oncogenic loci in gastric adenocarcinoma38,39, from non-neoplastic human gastric organoids (Fig. S1A).”
From Large-scale CRISPR screening in primary human 3D gastric organoids enables comprehensive dissection of gene-drug interactions (2025) · cites this paper as [38]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Fusobacterium spp. is important in the development and progression of gastrointestinal tumors1,19,34,35”
From RETRACTED ARTICLE: Microbiome analyses of blood and tissues suggest cancer diagnostic approach (2020) · cites this paper as [19]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008
Ferlay, J., Shin, H., Bray, F., Forman, D., Mathers, C., & Parkin, D. M. (2010) · International Journal of Cancer · doi:10.1002/ijc.25516 · Cited by 21,293
Comprehensive molecular characterization of human colon and rectal cancer
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11252 · Cited by 8,499
Self-citationLAURÉN, P. (1965) · Acta Pathologica Microbiologica Scandinavica · doi:10.1111/apm.1965.64.1.31 · Cited by 6,133
Integrated genomic characterization of endometrial carcinoma
The Cancer Genome Atlas Research Network, & Levine, D. A. (2013) · Nature · doi:10.1038/nature12113 · Cited by 5,784
Mutational heterogeneity in cancer and the search for new cancer-associated genes
Lawrence, M. S., Stojanov, P., Polak, P., Kryukov, G. V., Cibulskis, K., Sivachenko, A., Carter, S. L., Stewart, C., Mermel, C. H., Roberts, S. A., et al. (2013) · Nature · doi:10.1038/nature12213 · Cited by 5,461
Self-citationWHO Classification of Tumours of the Digestive System
Bosman, F. T. (2010) · Medical Entomology and Zoology · Cited by 5,041
Cell Migration: Integrating Signals from Front to Back
Ridley, A. J., Schwartz, M. A., Burridge, K., Firtel, R. A., Ginsberg, M. H., Borisy, G., Parsons, J. T., & Horwitz, A. R. (2003) · Science · doi:10.1126/science.1092053 · Cited by 4,978
Helicobacter pylori Infection and the Development of Gastric Cancer
Uemura, N., Okamoto, S., Yamamoto, S., Matsumura, N., Yamaguchi, S., Yamakido, M., Taniyama, K., Sasaki, N., & Schlemper, R. J. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa001999 · Cited by 4,465
The STATs of cancer — new molecular targets come of age
Yu, H., & Jove, R. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1275 · Cited by 2,278
Fuchs, C. S., Tomasek, J., Yong, C. J., Dumitru, F., Passalacqua, R., Goswami, C., Safran, H., dos Santos, L. V., Aprile, G., Ferry, D. R., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(13)61719-5 · Cited by 2,188
Research works printed but not linked: 2
- Ferlay, J. et al. GLOBOCAN 2012 v1.0, cancer incidence and mortality worldwide. IARC CancerBase 11, http://globocan.iarc.fr, accessed on January 15, 2014 (2013)
- The Cancer Genome Atlas Network Comprehensive molecular characterization of human colon and rectal cancer. Nature 487, 330–337 (2012) · DOI · Paper page
Cited by
Items 501–600 of 1,024
Chida, K., Kawazoe, A., Kawazu, M., Suzuki, T., Nakamura, Y., Nakatsura, T., Kuwata, T., Ueno, T., Kuboki, Y., Kotani, D., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-0401 · Cited by 110
“Moreover, previous reports demonstrated almost all MSI-H tumors show a highmutation load regardless of primary cancer sites (20, 21), whereas some reports about patients with various cancer types demonstrated that a few MSI-H patients did not show TMBH (22, 23).”
Hypoxia-Inducible lncRNA-AK058003 Promotes Gastric Cancer Metastasis by Targeting γ-Synuclein
Wang, Y., Liu, X., Zhang, H., Sun, L. J., Zhou, Y., Jin, H., Zhang, H., Zhang, H., Liu, J., Guo, H., et al. (2014) · Neoplasia · doi:10.1016/j.neo.2014.10.008 · Cited by 112
Prevalence and phenotypic correlations of EIF1AX mutations in thyroid nodules
Karunamurthy, A. D., Panebianco, F., Hsiao, S. J., Vorhauer, J., Nikiforova, M. N., Chiosea, S. I., & Nikiforov, Y. E. (2016) · Endocrine Related Cancer · doi:10.1530/erc-16-0043 · Cited by 124
Genomic Amplification of CD274 (PD-L1) in Small-Cell Lung Cancer
George, J., Saito, M., Tsuta, K., Iwakawa, R., Shiraishi, K., Scheel, A. H., Uchida, S., Watanabe, S.-I., Nishikawa, R., Noguchi, M., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1069 · Cited by 108
Pathogenesis of Gastric Cancer: Genetics and Molecular Classification
Figueiredo, C., Camargo, M. C., Leite, M., Fuentes‐Pananá, E. M., Rabkin, C. S., & Machado, J. C. (2017) · Current topics in microbiology and immunology · doi:10.1007/978-3-319-50520-6_12 · Cited by 130
Yamashita, S., Kishino, T., Takahashi, T., Shimazu, T., Charvat, H., Kakugawa, Y., Nakajima, T., Lee, Y.-C., Iida, N., Maeda, M., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1717340115 · Cited by 108
Wakatsuki, T., Yamamoto, N., Sano, T., Chìn, K., Kawachi, H., Takahari, D., Ogura, M., Ichimura, T., Nakayama, I., Osumi, H., et al. (2018) · Journal of Gastroenterology · doi:10.1007/s00535-018-1464-0 · Cited by 118
Catenacci, D. V. T., Rasco, D. W., Lee, J., Rha, S. Y., Lee, K., Bang, Y. J., Bendell, J. C., Enzinger, P. C., Marina, N. M., Xiang, H., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.01834 · Cited by 112
Seidlitz, T., Koo, B.-K., & Stange, D. E. (2021) · Cell Death & Differentiation · doi:10.1038/s41418-020-00662-2 · Cited by 108
Efficacy and predictive biomarkers of immunotherapy in Epstein-Barr virus-associated gastric cancer
Bai, Y., Xie, T., Wang, Z., Tong, S., Zhao, X., Zhao, F., Cai, J., Wei, X., Peng, Z., & Shen, L. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-004080 · Cited by 131
Zhao, L., Liu, Y., Zhang, S., Wei, L., Cheng, H., Wang, J., & Wang, J. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-04821-w · Cited by 124
“In 2014, the Cancer Genome Atlas (TCGA) Research Network reported the atlas results based on the detection of the genomes of 295 primary gastric adenocarcinomas [3].”
BackgroundLaskin, J., Jones, S., Aparicio, S., Chia, S., Ch'ng, C., Deyell, R., Eirew, P., Fok, A., Gelmon, K., Ho, C., et al. (2015) · Molecular Case Studies · doi:10.1101/mcs.a000570 · Cited by 109
Recent advances in the molecular diagnostics of gastric cancer
Kanda, M., & Kodera, Y. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i34.9838 · Cited by 113
Inflammation, DNA Damage, Helicobacter pylori and Gastric Tumorigenesis
Kalisperati, P., Spanou, E., Pateras, I. S., Korkolopoulou, P. A., Varvarigou, A. A., Karavokyros, I., Gorgoulis, V. G., Vlachoyiannopoulos, P. G., & Sougioultzis, S. (2017) · Frontiers in Genetics · doi:10.3389/fgene.2017.00020 · Cited by 127
Hilberg, F., Tontsch-Grunt, U., Baum, A., Le, A. T., Doebele, R. C., Lieb, S., Gianni, D., Voss, T., Garin‐Chesa, P., Haslinger, C., et al. (2017) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.117.244129 · Cited by 117
Molecular profiling of biliary tract cancer: a target rich disease
Jain, A., & Javle, M. M. (2016) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo.2016.09.01 · Cited by 113
Luo, X., Peng, X., Hou, J., Wu, S., Shen, J., & Wang, L. (2017) · International Journal of Nanomedicine · doi:10.2147/ijn.s137245 · Cited by 111
Kim, S. T., Banks, K. C., Pectasides, E., Kim, S. Y., Kim, K., Lanman, R. B., Talasaz, A., An, J., Choi, M. G., Lee, J. H., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy034 · Cited by 106
“Based on The Cancer Genome Atlas (TCGA) study, concomitant and recurrent focal amplifications were identified in ERBB2þ GC at the CCNE1, CDK6, EGFR, MET, and MYC loci [6].”
BackgroundProgress of Gastric Cancer Surgery in the era of Precision Medicine
Wang, Y., Zhang, L., Yang, Y., Lü, S., & Chen, H. (2021) · International Journal of Biological Sciences · doi:10.7150/ijbs.56735 · Cited by 117
Rosendahl Huber, A., Pleguezuelos-Manzano, C., Puschhof, J., Ubels, J., Boot, C., Saftien, A., Verheul, M., Trabut, L. T., Groenen, N., van Roosmalen, M., et al. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.02.009 · Cited by 106
Epstein–Barr virus-associated gastric cancer reveals intratumoral heterogeneity of PIK3CA mutations
Böger, C., Krüger, S., Behrens, H.-M., Bock, S., Haag, J., Kalthoff, H., & Röcken, C. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx047 · Cited by 110
Barbari, S. R., & Shcherbakova, P. V. (2017) · DNA repair · doi:10.1016/j.dnarep.2017.06.003 · Cited by 114
Pietrantonio, F., Fucà, G., Morano, F., Gloghini, A., Corso, S., Aprile, G., Perrone, F., Vita, F. D., Tamborini, E., Tomasello, G., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2781 · Cited by 111
Fewings, E., Larionov, A. A., Redman, J., Goldgraben, M. A., Scarth, J. A., Richardson, S., Brewer, C., Davidson, R., Ellis, I., Evans, D. G., et al. (2018) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(18)30079-7 · Cited by 118
Li, Y., Zhang, M., Dorfman, R. G., Pan, Y., Tang, D., Xu, L., Zhao, Z., Zhou, Q., Zhou, L., Wang, Y., et al. (2018) · Neoplasia · doi:10.1016/j.neo.2018.03.008 · Cited by 105
Future applications of FGF/FGFR inhibitors in cancer
Ghedini, G. C., Ronca, R., Presta, M., & Giacomini, A. (2018) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2018.1491795 · Cited by 105
Wang, Z., Liu, Y., & Niu, X. (2023) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2023.04.009 · Cited by 134
Patel, A. K., Sethi, N. S., & Park, H. (2026) · JAMA · doi:10.1001/jama.2025.20034 · Cited by 160
LncRNAs: Emerging Biomarkers in Gastric Cancer
Gu, Y., Chen, T., Li, G., Yu, X., Lu, Y., Wang, H., & Teng, L. (2015) · Future Oncology · doi:10.2217/fon.15.175 · Cited by 115
Carlomagno, N., Incollingo, P., Tammaro, V., Peluso, G., Rupealta, N., Chiacchio, G., Sandoval Sotelo, M. L., Minieri, G., Pisani, A., Riccio, E., et al. (2017) · BioMed Research International · doi:10.1155/2017/7869802 · Cited by 105
Patient-derived tumor-like cell clusters for drug testing in cancer therapy
Yin, S., Xi, R., Wu, A., Wang, S., Li, Y., Wang, C., Tang, L., Xia, Y., Yang, D., Li, J., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aaz1723 · Cited by 109
Grunberg, N., Pevsner-Fischer, M., Goshen-Lago, T., Diment, J., Stein, Y., Lavon, H., Mayer, S., Levi-Galibov, O., Friedman, G., Ofir-Birin, Y., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-2756 · Cited by 104
Global mapping of cancers: The Cancer Genome Atlas and beyond
Ganini, C., Amelio, I., Bertolo, R. G., Bove, P., Buonomo, O. C., Candi, E., Cipriani, C., Daniele, N. D., Juhl, H. H., Mauriello, A., et al. (2021) · Molecular Oncology · doi:10.1002/1878-0261.13056 · Cited by 121
Fatehullah, A., Terakado, Y., Sagiraju, S., Tan, T. L., Sheng, T., Tan, S., Murakami, K., Swathi, Y., Ang, N., Rajarethinam, R., et al. (2021) · Nature Cell Biology · doi:10.1038/s41556-021-00793-9 · Cited by 112
EBV-associated diseases: Current therapeutics and emerging technologies
Chakravorty, S., Afzali, B., & Kazemian, M. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1059133 · Cited by 121
on behalf of the AGAMENON study group, Fonseca, P. J., Carmona‐Bayonas, A., Hernández, R., Custodio, A., Cano, J. M., Lacalle, A., Echavarría, I., Macías, I., Mangas, M., et al. (2017) · British Journal of Cancer · doi:10.1038/bjc.2017.245 · Cited by 118
MicroRNA-647 Targets SRF-MYH9 Axis to Suppress Invasion and Metastasis of Gastric Cancer
Ye, G., Huang, K., Yu, J., Zhao, L., Zhu, X., Yang, Q., Li, W., Jiang, Y., Zhuang, B., Liu, H., et al. (2017) · Theranostics · doi:10.7150/thno.20512 · Cited by 104
“Because Rho-mediated pathways are closely associated with cancer metastasis and frequently activated in GC [7, 26], we selected out 5 candidate genes (SRF, ROCK1, ZAK, ELMO2, and MYH9) from Figure 2A (red marked) for further research, which were reported to be up-regulated in GC or associated with Rho-ROCK and Rho-MRT…”
BackgroundKong, F., Deng, X., Kong, X., Du, Y., Li, L., Zhu, H., Wang, Y., Xie, D., Guha, S., Li, Z., et al. (2018) · Oncogene · doi:10.1038/s41388-018-0387-9 · Cited by 124
Oue, N., Sentani, K., Sakamoto, N., Uraoka, N., & Yasui, W. (2019) · International Journal of Clinical Oncology · doi:10.1007/s10147-019-01443-9 · Cited by 123
Moehler, M. H., Al-Batran, S.-E., Andus, T., Arends, J., Arnold, D., Baretton, G. B., Bornschein, J., Budach, W., Daum, S., Dietrich, C. F., et al. (2019) · Zeitschrift für Gastroenterologie · doi:10.1055/a-1018-2516 · Cited by 118
Traditional Classification and Novel Subtyping Systems for Bladder Cancer
Zhu, S., Yu, W., Yang, X., Wu, C., & Fan, C. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00102 · Cited by 124
Xie, T., Liu, Y., Zhang, Z., Zhang, X., Gong, J., Qi, C., Li, J., Shen, L., & Peng, Z. (2020) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000316 · Cited by 118
Advances in the curative management of oesophageal cancer
Bolger, J. C., Donohoe, C. L., Lowery, M. A., & Reynolds, J. V. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01485-9 · Cited by 113
DDIT4 promotes gastric cancer proliferation and tumorigenesis through the p53 and MAPK pathways
Du, F., Sun, L., Chu, Y., Li, T., Lei, C., Wang, X., Jiang, M., Min, Y., Lu, Y., Zhao, X., et al. (2018) · Cancer Communications · doi:10.1186/s40880-018-0315-y · Cited by 103
“Genetic alterations are generally considered to drive cancer development and progression, and emerging evidence indicates that the complex molecular heterogeneity of GC underlies most, if not all, of the general ineffectiveness of current chemotherapeutics for GC [3].”
BackgroundGastric biomarkers: a global review
Baniak, N. M., Senger, J. B., Ahmed, S., Kanthan, S. C., & Kanthan, R. (2016) · World Journal of Surgical Oncology · doi:10.1186/s12957-016-0969-3 · Cited by 110
Wang, Y., Zhao, C., Chang, L., Jia, R., Liu, R., Zhang, Y., Gao, X., Li, J., Chen, R., Xia, X., et al. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.04.003 · Cited by 110
Huang, X., Pang, M.-J., Li, J.-Y., Chen, H., Sun, J., Song, Y., Ni, H.-J., Ye, S.-Y., Bai, S., Li, T., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-36310-9 · Cited by 122
Huang, K. K., Ma, H., Chong, R. H. H., Uchihara, T., Lian, B. S. X., Zhu, F., Sheng, T., Srivastava, S., Tay, S. T., Sundar, R., et al. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.10.004 · Cited by 121
Management of Patients With Adenocarcinoma or Squamous Cancer of the Esophagus
Ilson, D. H., & van Hillegersberg, R. (2017) · Gastroenterology · doi:10.1053/j.gastro.2017.09.048 · Cited by 110
Wu, Q., Xiang, S., Ma, J., Hui, P., Wang, T., Meng, W., Shi, M., & Wang, Y. (2018) · Molecular Oncology · doi:10.1002/1878-0261.12187 · Cited by 111
Wnt Signalling in Gastrointestinal Epithelial Stem Cells
Flanagan, D. J., Austin, C. R., Vincan, E., & Phesse, T. J. (2018) · Genes · doi:10.3390/genes9040178 · Cited by 121
A machine learning approach for somatic mutation discovery
Wood, D. E., White, J. R., Georgiadis, A., Van Emburgh, B., Parpart-Li, S., Mitchell, J., Anagnostou, V., Niknafs, N., Karchin, R., Papp, E., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aar7939 · Cited by 103
Dissection of gastric cancer heterogeneity for precision oncology
Ho, S. W. T., & Tan, P. B. O. (2019) · Cancer Science · doi:10.1111/cas.14191 · Cited by 110
Tanaka, Y., Chiwaki, F., Kojima, S., Kawazu, M., Komatsu, M., Ueno, T., Inoue, S., Sekine, S., Matsusaki, K., Matsushita, H., et al. (2021) · Nature Cancer · doi:10.1038/s43018-021-00240-6 · Cited by 111
Dal Molin, M., Zhang, M., de Wilde, R. F., Ottenhof, N. A., Rezaee, N., Wolfgang, C. L., Blackford, A., Vogelstein, B., Kinzler, K. W., Papadopoulos, N., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2600 · Cited by 101
Gastric Lgr5+ stem cells are the cellular origin of invasive intestinal-type gastric cancer in mice
Li, X.-B., Yang, G., Zhu, L., Tang, Y., Zhang, C., Ju, Z., Yang, X. Y., & Teng, Y. (2016) · Cell Research · doi:10.1038/cr.2016.47 · Cited by 108
Rho GTPases: Anti- or pro-neoplastic targets?
Zandvakili, I., Lin, Y., Morris, J. C., & Zheng, Y. (2016) · Oncogene · doi:10.1038/onc.2016.473 · Cited by 107
ECCO essential requirements for quality cancer care: Oesophageal and gastric cancer
Allum, W., Lordick, F., Alsina, M., Andritsch, E., Ba‐Ssalamah, A., Beishon, M., Braga, M., Caballero, C. A., Carneiro, F., Cassinello, F., et al. (2018) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2017.12.019 · Cited by 118
Epstein-Barr Virus MicroRNA miR-BART5-3p Inhibits p53 Expression
Zheng, X., Wang, J., Wei, L., Qiu, P., Gao, Y., Fu, Y., Lu, Y., Qin, Z., Zhang, X., Lu, J., et al. (2018) · Journal of Virology · doi:10.1128/jvi.01022-18 · Cited by 104
Raynaud, F., Mina, M., Tavernari, D., & Ciriello, G. (2018) · PLoS Genetics · doi:10.1371/journal.pgen.1007669 · Cited by 109
Xiao, Y., Wu, J., Lin, Z., & Zhao, X. (2018) · Computer Methods and Programs in Biomedicine · doi:10.1016/j.cmpb.2018.10.004 · Cited by 101
In silico analyses for potential key genes associated with gastric cancer
Yan, P., He, Y., Xie, K., Kong, S., & Zhao, W. (2018) · PeerJ · doi:10.7717/peerj.6092 · Cited by 101
Emergence of ERBB2 Mutation as a Biomarker and an Actionable Target in Solid Cancers
Subramanian, J., Katta, A., Masood, A., Vudem, D. R., & Kancha, R. K. (2019) · The Oncologist · doi:10.1634/theoncologist.2018-0845 · Cited by 111
Epstein–Barr virus‐derived circular RNA LMP2A induces stemness in EBV‐associated gastric cancer
Gong, L., Chen, J., Dong, M., Xiao, Z., Feng, Z., Pan, Y., Zhang, Y., Du, Y., Zhang, J., Bi, Y.-H., et al. (2020) · EMBO Reports · doi:10.15252/embr.201949689 · Cited by 102
“In our previous study, ebv-circRNA was found to be expressed in several EBV-positive malignancies, including Burkitt lymphoma, EBVaGC and NPC (Huang et al , 2019), suggesting that ebv-circRNAs may play an important role in maintaining the tumour phenotype.”
InfluentialTumor-promoting macrophages prevail in malignant ascites of advanced gastric cancer
Eum, H. H., Kwon, M., Ryu, D., Jo, A., Chung, W., Kim, N., Hong, Y., Son, D., Kim, S. T., Lee, J., et al. (2020) · Experimental & Molecular Medicine · doi:10.1038/s12276-020-00538-y · Cited by 110
Anatomic position determines oncogenic specificity in melanoma
Weiss, J. M., Hunter, M. V., Cruz, N. M., Baggiolini, A., Tagore, M., Ma, Y., Misale, S., Marasco, M., Simon-Vermot, T., Campbell, N. R., et al. (2022) · Nature · doi:10.1038/s41586-022-04584-6 · Cited by 101
Strong, V. E. M. (2018) · Updates in Surgery · doi:10.1007/s13304-018-0543-3 · Cited by 101
Increased BTLA and HVEM in gastric cancer are associated with progression and poor prognosis
Lan, X., Li, S., Gao, H., Nanding, A., Quan, L., Yang, C., Ding, S., & Xue, Y. (2017) · OncoTargets and Therapy · doi:10.2147/ott.s128825 · Cited by 106
Genome-wide DNA methylation analysis reveals molecular subtypes of pancreatic cancer
Mishra, N. K., & Guda, C. (2017) · Oncotarget · doi:10.18632/oncotarget.15993 · Cited by 104
Corso, S., Isella, C., Bellomo, S. E., Apicella, M., Durando, S., Migliore, C., Ughetto, S., D’Errico, L., Menegon, S., Moya-Rull, D., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-19-1166 · Cited by 100
Budczies, J., Bockmayr, M., Denkert, C., Klauschen, F., Gröschel, S., Darb‐Esfahani, S., Pfarr, N., Leichsenring, J., Onozato, M. L., Lennerz, J. K., et al. (2016) · Genes, Chromosomes and Cancer · doi:10.1002/gcc.22365 · Cited by 99
EZH2 in Cancer Progression and Potential Application in Cancer Therapy: A Friend or Foe?
Yan, K.-S., Lin, C., Liao, T.-W., Peng, C.-M., Lee, S.-C., Liu, Y., Chan, W. P., & Chou, R. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18061172 · Cited by 101
Estrogen-related receptor gamma functions as a tumor suppressor in gastric cancer
Kang, M. H., Choi, H., Oshima, M., Cheong, J., Kim, S., Lee, J. H., Park, Y. S., Choi, H., Kweon, M., Pack, C., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-04244-2 · Cited by 109
Yang, Z., Li, C., Yan, C., Li, J., Yan, M., Liu, B., Zhu, Z., Wu, Y., & Gu, Q. (2018) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2018.10.039 · Cited by 103
Identifying Epistasis in Cancer Genomes: A Delicate Affair
van de Haar, J., Canisius, S., Yu, M., Voest, E. E., Wessels, L. F. A., & Ideker, T. (2019) · Cell · doi:10.1016/j.cell.2019.05.005 · Cited by 99
H. pylori infection alters repair of DNA double-strand breaks via SNHG17
Han, T., Jing, X., Bao, J., Zhao, L., Zhang, A., Miao, R., Guo, H., Zhou, B., Zhang, S., Sun, J., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci125581 · Cited by 100
Identification of low abundance microbiome in clinical samples using whole genome sequencing
Zhang, C., Cleveland, K., Schnoll-Sussman, F., McClure, B., Bigg, M., Thakkar, P., Schultz, N., Shah, M. A., & Betel, D. (2015) · Genome Biology · doi:10.1186/s13059-015-0821-z · Cited by 96
Luo, X., Hong, L., Cheng, C., Li, N., Zhao, X., Shi, F., Liu, J., Fan, J., Zhou, J., Bode, A. M., et al. (2018) · Cell Death and Disease · doi:10.1038/s41419-018-0662-2 · Cited by 104
Muenst, S., Soysal, S. D., Tzankov, A., & Hoeller, S. (2015) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2014.980235 · Cited by 97
Inaguma, S., Wang, Z., Lasota, J., Sarlomo-Rikala, M., McCue, P. A., Ikeda, H., & Miettinen, M. (2016) · American Journal of Surgical Pathology · doi:10.1097/pas.0000000000000653 · Cited by 97
Ahn, S., Lee, S.-J., Kim, Y., Kim, A., Shin, N., Choi, K. U., Lee, C., Huh, G. Y., Kim, K.-M., Setia, N., et al. (2016) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000000756 · Cited by 101
EBV-associated gastric cancer evades T-cell immunity by PD-1/PD-L1 interactions
Sasaki, S., Nishikawa, J., Sakai, K., Iizasa, H., Yoshiyama, H., Yanagihara, M., Shuto, T., Shimokuri, K., Kanda, T., Suehiro, Y., et al. (2018) · Gastric Cancer · doi:10.1007/s10120-018-0880-4 · Cited by 104
Wang, Y., Sun, L. N., Li, Z., Gao, J., Ge, S., Zhang, C., Yuan, J., Wang, X., Li, J., Lü, Z., et al. (2019) · Gastric Cancer · doi:10.1007/s10120-019-00965-5 · Cited by 104
Precision medicine in gastric cancer
Bonelli, P., Borrelli, A., Tuccillo, F. M., Silvestro, L., Palaia, R., & Buonaguro, F. M. (2019) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v11.i10.804 · Cited by 124
Okabe, A., Huang, K. K., Matsusaka, K., Fukuyo, M., Xing, M., Ong, X., Hoshii, T., Usui, G., Seki, M., Mano, Y., et al. (2020) · Nature Genetics · doi:10.1038/s41588-020-0665-7 · Cited by 107
Murine Models of Gastric Corpus Preneoplasia
Petersen, C. P., Mills, J. C., & Goldenring, J. R. (2016) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2016.11.001 · Cited by 104
Harada, K., Dong, X., Estrella, J. S., Correa, A. M., Xu, Y., Hofstetter, W. L., Sudo, K., Onodera, H., Suzuki, K., Suzuki, A., et al. (2017) · Gastric Cancer · doi:10.1007/s10120-017-0760-3 · Cited by 104
Molecular landscape of esophageal cancer: implications for early detection and personalized therapy
Talukdar, F. R., di Pietro, M., Secrier, M., Moehler, M. H., Goepfert, K., Soares‐Lima, S. C., Pinto, L. F. R., Hendricks, D. T., Parker, M. I., & Herceg, Z. (2018) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.13876 · Cited by 104
Ye, T., Yang, M., Huang, D., Wang, X., Xue, B., Tian, N., Xu, X., Bao, L., Hu, H., Lv, T., et al. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1074-6 · Cited by 95
“Introduction Gastric cancer (GC) is the fourth leading cause of cancer-related death worldwide [1, 2].”
BackgroundJiang, Y., Wang, Y., Chen, G., Sun, F., Wu, Q., Huang, Q., Zeng, D., Qiu, W., Wang, J., Yao, Z., et al. (2024) · Cell Metabolism · doi:10.1016/j.cmet.2024.05.013 · Cited by 107
Zhang, J., Huang, J., Chen, Y., Yuan, F., Zhang, H., Yan, F. H., Wang, M., Wang, G., Su, M., Lu, G., et al. (2015) · Scientific Reports · doi:10.1038/srep13750 · Cited by 98
Yoon, C., Cho, S., Aksoy, B. A., Park, D. J., Schultz, N. D., Ryeom, S. W., & Yoon, S. S. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1356 · Cited by 94
RetractedYamamoto, H., Watanabe, Y., Oikawa, R., Morita, R., Yoshida, Y., Maehata, T., Yasuda, H., & Itoh, F. (2016) · Clinical and Translational Gastroenterology · doi:10.1038/ctg.2016.40 · Cited by 94
Chmielecki, J., Bailey, M., He, J., Elvin, J. A., Vergilio, J., Ramkissoon, S. H., Suh, J. H., Frampton, G. M., Sun, J., Morley, S., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-1106 · Cited by 102
Perspectives of HER2-targeting in gastric and esophageal cancer
Gerson, J. N., Skariah, S., Denlinger, C. S., & Astsaturov, I. A. (2017) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2017.1315406 · Cited by 100
Tumor Immunity and Survival as a Function of Alternative Neopeptides in Human Cancer
Rech, A. J., Balli, D., Mantero, A., Ishwaran, H., Nathanson, K. L., Stanger, B. Z., & Vonderheide, R. H. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0559 · Cited by 94
Genetic Alterations of TRAF Proteins in Human Cancers
Zhu, S., Jin, J., Gokhale, S., Lu, A. M., Shan, H., Feng, J., & Xie, P. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02111 · Cited by 108
“Missense mutations at R376 (R376W or Q) located in the linker between the coiled-coil and TRAF-C domains of TRAF3 are detected in six patients with lung cancer, CRC, SSCC, and melanoma (TCGA; COSMIC) (14, 108, 169).”
BackgroundInfluentialResolving gastric cancer aetiology: an update in genetic predisposition
Lott, P. C., & Carvajal‐Carmona, L. G. (2018) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(18)30237-1 · Cited by 108
Targeted therapies in metastatic gastric cancer: Current knowledge and future perspectives
Pellino, A., Riello, E., Nappo, F., Brignola, S., Murgioni, S., Djaballah, S. A., Lonardi, S., Zagonel, V., Rugge, M., Loupakis, F., et al. (2019) · World Journal of Gastroenterology · doi:10.3748/wjg.v25.i38.5773 · Cited by 101
Tzeng, H., Chyuan, I., & Lai, J. (2021) · Biochemical Pharmacology · doi:10.1016/j.bcp.2021.114760 · Cited by 100
Metadata
- Authors
- The Cancer Genome Atlas Research Network
- Venue
- Nature
- Published
- 2014-07-23
- Volume
- 513
- Issue
- 7517
- Pages
- 202-209
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC4170219
- OpenAlex
- W2126547130
- Cited by
- 6,498
- References
- 43
- Citations by year
- 2026: 455 · 2025: 481 · 2024: 569 · 2023: 637 · 2022: 620 · 2021: 737 · 2020: 653 · 2019: 554 · 2018: 560 · 2017: 490 · 2016: 398 · 2015: 297 · 2014: 41
- FWCI
- 327.21
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-sa
- creativecommons.org/licenses/by-nc-sa/3.0/ (tdm)
- creativecommons.org/licenses/by-nc-sa/3.0/ (vor)
- Locations
- Nature (publishedVersion, cc-by-nc-sa)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-sa)
- PubMed Central (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- YUHSpace (Yonsei University Medical Library) (submittedVersion, cc-by-nc-nd)
- Minerva Access (University of Melbourne) (submittedVersion, cc-by-nc-sa)
- KUMeL Repository (Keimyung University) (submittedVersion, cc-by-nc-nd)
- Scholarworks@UNIST (Ulsan National Institute of Science and Technology) (submittedVersion)
- Funders
- National Institutes of Health
- National Human Genome Research Institute (U54HG003067, R01HG007069, U54HG003079, U54HG003273, R01HG005690)
- National Cancer Institute (P30CA16672, K08CA134931, P50CA098258, U24CA143882, P01CA028842, R01CA180006, U24CA143843, U24CA143840, U24CA143858, U24CA126543, U24CA144025, U24CA143866, U24CA143883, U24CA143845, U24CA180951, U24CA143867, U24CA143848, U24CA143799, U24CA143835, K99CA166729, P30CA008748, P30CA016672, P30CA006973)
- Topics
- Health Sciences › Medicine › Oncology › Gastric Cancer Management and Outcomes
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal Tumor Research and Treatment
- Keywords
- gastric adenocarcinoma, molecular classification, Epstein-Barr virus, PIK3CA mutation, DNA hypermethylation, PD-L1, PD-L2, microsatellite instability, chromosomal instability, genome stability, RHOA mutations, aneuploidy, targeted therapy, patient stratification
- MeSH terms
- Adenocarcinoma, Herpesvirus 4, Human, Female, Humans, Male, Mutation, Stomach Neoplasms, Genome, Human, Gene Expression Regulation, Neoplastic, Proteome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.